Prognostic Implications of Chronic Kidney Disease Stage on Outcomes After Percutaneous Coronary Intervention
by
, , , , ,
Keren Skalsky
1,2,*,
Yeela Talmor-Barkan
1,2,
Edward Itelman
1,2,
Tsahi T. Lerman
1,2,
Assaf Rotmensh
1,2,
Leor Perl
1,2
,
Alon Shechter
1,2
,
Yaron Shapira
1,2,
Arthur Shiyovich
3,4
,
Ran Kornowski
1,2 and
Amos Levi
1,2 1
Department of Cardiology, Rabin Medical Center, Petach-Tikva 4941492, Israel
2
Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 02115, Israel
3
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
4
Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
*
Author to whom correspondence should be addressed.
J. Cardiovasc. Dev. Dis. 2026, 13(1), 4; https://doi.org/10.3390/jcdd13010004
Submission received: 19 November 2025
/
Revised: 12 December 2025
/
Accepted: 17 December 2025
/
Published: 20 December 2025
(This article belongs to the Topic Cardiovascular Disease in Special Populations: From Basic Science to Clinical Practice)
Abstract
Aims: Chronic kidney disease (CKD) is associated with adverse cardiovascular outcomes, yet few contemporary studies stratify outcomes by specific CKD stages in the era of modern percutaneous coronary intervention (PCI) techniques and new-generation drug-eluting stents (DESs). We aim to assess the relationship between CKD and post-PCI outcomes in an updated, stage-specific, and long-term cohort. Methods: We retrospectively analyzed 11,489 patients who underwent PCI between 2010 and 2020. Kidney function was classified as preserved (eGFR ≥ 60 mL/min/1.73 m2), stage III CKD (eGFR 30–59), or stage IV/V CKD (eGFR < 30) using the CKD-EPI equation. The primary endpoint was a composite of all-cause mortality, non-fatal myocardial infarction (MI), and target vessel revascularization (TVR) at 1 year; secondary endpoints included individual components and outcomes through 5 years. Associations were evaluated using multivariable Cox regression. Results: Stage III and stage IV/V CKD were present in 18% and 5.6% of patients, respectively. At 1 year, both stage III (HR 2.13, p < 0.01) and stage IV/V CKD (HR 4.91, p < 0.01) were associated with higher risk of the composite endpoint. Mortality rose sharply with CKD severity (33% in stage IV/V vs. 4% in preserved renal function), and MI risk was significantly higher in stage IV/V CKD. These associations persisted after 5 years. Unadjusted TVR risk was higher in stage IV/V CKD but lost significance after adjustment. Conclusions: CKD, particularly in advanced stages, is independently associated with increased mortality and MI after PCI, with effects persisting in the long term. While advanced CKD showed higher unadjusted TVR risk, this was not independent after adjustment. These findings support individualized treatment strategies and extended follow-up in PCI patients with CKD.
1. Introduction
Chronic kidney disease (CKD) is a well-established independent risk factor for adverse cardiovascular outcomes, including coronary artery disease (CAD) [1,2]. The prevalence and severity of CAD increase progressively as kidney function declines, with patients in advanced stages of CKD (stages IV/V) facing particularly high risks of cardiovascular events and mortality compared to those with preserved renal function [3,4]. Despite advances in percutaneous coronary intervention (PCI) techniques, current evidence suggests that individuals with CKD, especially those with advanced disease, remain at an elevated risk of complications such as target vessel revascularization (TVR) and myocardial infarction (MI) following complex PCI [5,6]. While the association between CKD and adverse cardiovascular outcomes is well established, fewer contemporary studies stratify outcomes by specific CKD stages in the era of modern PCI techniques and second-/third-generation DES.
Understanding how varying degrees of renal dysfunction affect post-PCI outcomes is essential for optimizing management strategies in this high-risk population. In this study, we aimed to evaluate the incidence of all-cause mortality, TVR and MI following PCI across different stages of CKD.
2. Materials and Methods
2.1. Study Population
We conducted a retrospective analysis of 11,489 patients who underwent PCI between 2010 and 2020 at Rabin Medical Center. CKD was defined using the CKD-EPI equation, categorizing patients into preserved kidney function (eGFR ≥ 60 mL/min/1.73 m2, including CKD stage I/II), CKD stage III (eGFR 30–59 mL/min/1.73 m2) and CKD stage IV/V (eGFR < 30 mL/min/1.73 m2), also referred as advanced CKD [7]. The study included all PCI with exception, including patients with recurrent lesions and post CABG.
2.2. Follow-Up and Outcomes
Patients were followed from the time of PCI until death or up to five years, whichever occurred first. The primary endpoint was a composite of all-cause mortality, non-fatal MI and TVR at one year. Secondary outcomes included each of the components of the primary outcome in separate. Long-term outcomes up to five years were assessed. Mortality data were obtained from the Israeli Ministry of the Interior’s Population Registry.
2.3. Data Collection and Definitions
CKD diagnosis was based on the most recent creatinine level recorded within three months prior to the PCI procedure. eGFR was calculated using the CKD-EPI equation [8]. Patients with an eGFR of 30–59 mL/min/1.73 m2 were classified as CKD stage III, those with 15–29 mL/min/1.73 m2 as stage IV, and those with eGFR < 15 mL/min/1.73 m2 or requiring renal replacement therapy as stage V [7].
Baseline comorbidities were recorded according to physician documentation at the time of PCI. Obstructive coronary artery disease was defined as angiographic stenosis ≥ 70% in a vessel with a diameter ≥ 2 mm, ≥50% in the left main, or a fractional flow reserve (FFR) < 0.80. Severe left ventricular dysfunction was defined as an ejection fraction < 30% based on the initial echocardiogram during hospitalization [9]. Reinterventions were captured as TVR, defined as repeat PCI or CABG of the index vessel.
2.4. Statistical Analysis
Continuous variables were presented as means ± standard deviation (SD) or medians with interquartile ranges (IQR), as appropriate. Group comparisons for continuous variables were performed using one-way ANOVA or the Kruskal–Wallis test, depending on data distribution. Categorical variables were reported as counts and percentages and compared using the chi-squared test. For pairwise comparisons between two groups, the chi-squared test was used for categorical variables, and either Student’s t-test or the Mann–Whitney–Wilcoxon test was applied for continuous variables, based on the normality of the data’s distribution. As a secondary analysis, we performed a competing risk analysis to account for the influence of death on the incidence of TVR and re-MI. The Fine and Gray sub distribution hazard model was used to estimate the cumulative incidence function, treating death as a competing event. Sub distribution hazard ratios (sHRs) and 95% confidence intervals (CIs) were calculated.
All statistical tests were two-sided, and a p-value < 0.05 was considered significant. Hazard ratios (HR) are presented with 95% confidence intervals (CI). Kaplan–Meier survival curves were generated, and the log-rank test was used to compare survival rates across groups at one and five years. Cox proportional hazards models were used to assess the association between CKD stage and outcomes (TVR, MI, mortality), adjusting for relevant covariates identified in univariate analyses (p < 0.05). Final adjusted models included age, sex, diabetes, prior stroke, COPD, PVD, ACS/MI at presentation, radial vs. femoral access, LVEF, atrial fibrillation, and congestive heart failure. All analyses were performed using R (version 4.0.0, RStudio, Vienna, Austria).
3. Results
3.1. Study Population and Strata
Between 2010 and 2020, 11,489 patients underwent PCI at Rabin Medical Center. Among these, 2708 (23.6%) were identified as having CKD, including 2063 patients (18%) with stage III CKD and 645 patients (5.6%) with stage IV/V CKD.
The study population was predominantly older adults. The mean age was 72.5 years for patients with CKD stage IV/V, 75.0 years for stage III, and 63.4 years for those with preserved renal function. Approximately one-third of the cohort was female, with lower proportions in earlier CKD stages. Cardiovascular risk factors, including diabetes mellitus, hypertension, smoking, and chronic obstructive pulmonary disease (COPD) were more prevalent with increasing CKD severity. Likewise, prior stroke and peripheral vascular disease were more common in advanced CKD stages (Table 1).
Cardiac conditions such as congestive heart failure and reduced ejection fraction were also more frequent in patients with stage IV/V CKD. Additionally, lipid profiles (total cholesterol and LDL) tended to be lower among patients with advanced CKD.
PCI indications and procedural characteristics differed by CKD stage. The proportion of interventions for acute coronary syndromes decreased from 67.9% in patients with preserved renal function to 55.5% in those with stage IV/V CKD. Left main coronary interventions were more frequent in advanced CKD, while intervention distribution across other coronary territories was similar. Femoral artery access was used more often than radial access in patients with advanced CKD (Table 1).
Drug-eluting stents were used almost exclusively. Several drug-eluting stent platforms were employed during the study period, including Xience (everolimus-eluting stent, Abbott Vascular, Santa Clara, CA, USA), Onyx (zotarolimus-eluting stent, Medtronic, Santa Rosa, CA, USA), BioMatrix (biolimus-A9–eluting stent, Biosensors International, Singapore), Orsiro (sirolimus-eluting stent, Biotronik, Bülach, Switzerland), and Ultimaster (sirolimus-eluting stent, Terumo, Tokyo, Japan). Xience was the most commonly used platform.
3.2. Follow-Up and Outcomes
CKD stages III and IV/V were associated with increased rates of the composite outcome including all-cause mortality, non-fatal MI and TVR at 1 year. Patients with CKD stage III were at 2.13 fold risk for mortality, MI or TVR (95% CI 1.9–2.4, p < 0.01). This risk increased to 4.91 among patients with CKD stage IV/V (95% CI 4.28–5.63, p < 0.01) (Table 2, Figure 1).
All-cause 33. in patients with CKD stage IV/V, compared to 14.1% in patients with CKD stage III and 4% among patients with preserved kidney function. Kaplan–Meier curves depicting mortality by CKD stage are presented in Figure 2.
The increased rates of non-fatal MI were consistent in all CKD stages, with HR of 2.29 (95% CI 1.78–2.95, p < 0.01) at stage IV/V and 1.31 (95% CI 1.1–1.6, p < 0.01) at stage III CKD. CKD stage IV/V was associated with an increased risk of TVR (HR 1.67, 95% CI 1.07–2.61, p = 0.02), whereas this association was not significant for CKD stage III.
The associations of CKD with the composite primary outcome, as well as all-cause mortality and non-fatal MI continued through the five-year follow-up. Patients with advanced CKD had 4.63 fold risk of experiencing death, MI or TVR (95% CI 4.16–5.15) compared to patients with preserved kidney function. This risk was 2.22 fold higher for patients with CKD stage III (95% CI 2.05–2.4).
Five-year mortality was 57% in patients with CKD stage IV/V, compared to 10.5% in patients with preserved kidney function. The hazard ratio for MI at five years was 2.09 (95% CI 1.7–2.57, p < 0.001) and 1.29 (95% CI 1.2–1.47, p < 0.001) in advanced CKD and at CKD stage III, respectively.
At five years, the risk of TVR in CKD stage IV/V did not reach statistical significance (HR 1.37, 95% CI 0.94–2.02, p = 0.104) (Table 2).
3.3. Multivariable and Competing Risk Analysis
After adjustment, stage IV/V remained independently associated with the primary composite outcome at 1 year (HR 3.00, 95% CI 2.58–3.49, p < 0.001) and 5 years (HR 2.78, 95% CI 2.48–3.13, p < 0.001). The adjusted risk for CKD stage III was 1.46 (95% CI 1.29–1.65, p < 0.001) at 1 year and 1.49 (95% CI 1.37–1.63) at 5 years (Table 3).
Table 4.
Multivariable analysis for all-cause mortality at 1 year and at 5 years.
| Variable | 1-Year HR (95% CI) | p-Value | 5-Year HR (95% CI) | p-Value |
|---|---|---|---|---|
| CKD Stage | ||||
| IV/V | 4.73 (3.90–5.73) | <0.001 | 4.13 (3.60–4.73) | <0.001 |
| III | 2.18 (1.85–2.58) | <0.001 | 2.15 (1.93–2.38) | <0.001 |
| Adjusted Variables | ||||
| Age (per year) | 1.03 (1.02–1.03) | <0.001 | 1.03 (1.03–1.03) | <0.001 |
| Female gender | 1.29 (1.11–1.49) | <0.001 | 1.20 (1.09–1.32) | <0.001 |
| Diabetes mellitus | 1.01 (0.88–1.16) | 0.913 | 1.20 (1.10–1.32) | <0.001 |
| MI or ACS (non-elective PCI) | 1.17 (1.01–1.35) | 0.032 | 0.97 (0.89–1.07) | 0.536 |
| Moderate-to-severe LV dysfunction | 2.46 (2.13–2.84) | <0.001 | 2.09 (1.90–2.30) | <0.001 |
| Atrial fibrillation | 0.58 (0.42–0.80) | <0.001 | 0.94 (0.80–1.10) | 0.422 |
| Peripheral vascular disease | 1.49 (1.17–1.90) | 0.001 | 1.78 (1.52–2.09) | <0.001 |
| COPD | 1.57 (1.31–1.88) | <0.001 | 1.64 (1.45–1.85) | <0.001 |
| Radial approach | 0.50 (0.44–0.58) | <0.001 | 0.68 (0.62–0.75) | <0.001 |
| Prior stroke | 1.17 (0.95–1.44) | 0.145 | 1.29 (1.13–1.48) | <0.001 |
| Congestive heart failure | 0.65 (0.51–0.83) | <0.001 | 1.06 (0.94–1.21) | 0.355 |
The increased risk of MI in CKD stage IV/V remained significant after multivariable adjustment at both 1 and 5 years. However, CKD stage III was not independently associated with increased MI risk (Table 5).
The association between advanced CKD and TVR was attenuated after adjustment, with no independent association observed for either 1-year or 5-year follow-up (Table 6).
Other predictors of increased mortality included older age (≥65 years), female sex, peripheral vascular disease, diabetes, COPD, femoral vs. radial access, and severe left ventricular dysfunction. These findings were consistent in competing risk models (Supplementary Materials Table S1).
4. Discussion
In this large retrospective cohort study, we evaluated the impact of CKD severity on cardiovascular outcomes following PCI. Worsening CKD stage was strongly and consistently associated with adverse outcomes. Advanced CKD (stage IV/V) conferred more than a fourfold higher risk of the composite endpoint of death, MI, or TVR at both 1 and 5 years, while stage III CKD carried approximately a twofold increased risk. Mortality risk rose steeply with declining renal function, reaching 57% at 5 years in stage IV/V. Although MI risk remained elevated in advanced CKD after adjustment, the association with TVR was attenuated and no longer significant.
These results are strongly supported by the literature. Multiple large cohort studies and registries have demonstrated a stepwise increase in mortality and major adverse cardiovascular events (MACE) with worsening CKD stage after PCI, even after multivariable adjustment for confounders [10,11,12,13]. For example, the J-MINUET study found that three-year mortality and MACE rates rise sharply from patients with preserved kidney function to those with moderate and severe CKD, and that CKD stage improved risk prediction models for adverse outcomes [12]. Those findings are also supported by meta-analysis demonstrating that CKD is an independent predictor of mortality and MI after PCI, with risk increasing as eGFR declines [14].
Several pathophysiological mechanisms probably contribute to the poor post-PCI outcomes observed in patients with CKD. Chronic kidney dysfunction is associated with systemic inflammation, oxidative stress, endothelial dysfunction, and as a result accelerated atherosclerosis, increased risk for restenosis or therefore recurrent ischemia [15,16,17]. Additional mechanism is uremia-related platelet dysfunction and impaired drug metabolism that may compromise both procedural success and antiplatelet efficacy [18,19].
The increased rate of femoral access and higher interventional complexity in patients with advanced CKD stages, as seen in our cohort, may further contribute to the increased procedural risk and worse outcomes.
The association between CKD and restenosis or stent thrombosis remains incompletely understood. Much of the existing evidence is based on earlier-generation stent platforms and outdated interventional techniques. The SYNTAX trial, which utilized paclitaxel-eluting stents, reported worse outcomes and higher restenosis rates in patients with eGFR < 30 mL/min/1.73 m2 or dialysis dependence. However, its five-year follow-up failed to establish a significant link between CKD and TVR [20]. Other trials, including a 2016 Korean study, showed that individuals with advanced CKD experienced higher rates of target lesion failure, even with second-generation drug-eluting stents [5]. In contrast, findings from the HORIZONS-AMI trial indicated no significant association between CKD and TVR at 30 days, 1 year, or 3 years [14,21]. Furthermore, in that same trial, no difference in TVR rates was observed between bare-metal and drug-eluting stents in CKD patients at 3-year follow-up [21]. In our cohort, the association between CKD and TVR was modest. A statistically significant association was observed at one year in patients with stage IV/V CKD, but this association diminished over time and was no longer significant after adjusting for confounding variables and competing risks. Multivariate analysis revealed that neither stage III nor stage IV/V CKD independently predicted TVR. These findings suggest that MI in this cohort was more likely driven by de novo lesions rather than stent failure. Advanced CKD may serve as a surrogate marker for higher TVR risk, rather than being a direct causal factor.
In the present cohort, the association between CKD and TVR was modest. A statistically significant association was observed at one year among patients with stage IV/V CKD; however, this association attenuated over time and was no longer significant after adjustment for confounding variables and competing risks. On multivariable analysis, neither stage III nor stage IV/V CKD independently predicted TVR. These findings suggest that subsequent myocardial infarction in this population may be more frequently attributable to de novo coronary lesions rather than stent-related failure, consistent with the systemic inflammatory milieu and accelerated atherosclerotic progression observed in advanced CKD. Additional explanations may include differences in lesion complexity, as reflected by higher rates of left main and graft PCI in advanced CKD, as well as lower radial access use and a greater comorbidity burden, which may influence the threshold for repeat revascularization.
Importantly, although competing risk methodology was applied, the substantially higher mortality observed in patients with advanced CKD continues to exert a strong influence on long-term revascularization outcomes. This observation supports the interpretation that advanced CKD may function as a marker of overall disease severity and adverse vascular biology rather than serving as an independent causal determinant of TVR.
Our study has several notable strengths that enhance the robustness and relevance of these findings. First, it represents one of the largest and most contemporary real-world cohorts to date evaluating the prognostic impact of CKD stage on PCI outcomes, encompassing over 11,000 patients treated within the last decade. Second, the analysis specifically examined TVR as a distinct endpoint, which has been underreported in prior CKD-PCI research. Importantly, the study reflects current clinical practice in the era of latest-generation drug-eluting stents, advanced interventional techniques, and contemporary pharmacological therapies, thereby providing relevant insights for present-day patient management. The inclusion of both short- and long-term follow-up strengthens the validity of the findings and allows for a comprehensive assessment of temporal trends in risk. Finally, the use of detailed multivariable and competing risk analyses enhances the robustness of the results and supports their applicability to a broad PCI population.
As CKD is becoming a growing global health burden, a substantial proportion of patients undergoing PCI have some degree of renal impairment. Renal dysfunction is independently associated with increased cardio-vascular risk. Whether PCI modifies this risk remains uncertain.
The ISCHEMIA-CKD trial evaluated elective patients with advanced CKD (stages 4–5 or dialysis-dependent) and failed to find benefit of invasive strategy of revascularization (PCI or CABG) over optimal medical therapy. However, interpretation of these results should be cautious, as the trial excluded patients with severe symptoms, left main disease, or systolic heart failure. Additionally, crossover between treatment arms was frequent, and peri-procedural MI rates were higher in the intervention group compared to the conservative treatment group [22,23].
Unlike elective procedures, in the acute setting, PCI remains a necessary and often life-saving intervention unrelated to CKD severity. Data from the SWEDEHEART registry demonstrated improved one-year survival with an early invasive strategy in patients with NSTEMI and CKD stages 2–4; nevertheless, the benefit of invasive strategy declined with progression of the kidney failure and was less evident in stage 5 CKD and in dialysis patients [24]. However, more recent and up to date study have supported invasive management in patients with acute MI in all stages of CKD patients including those on hemodialysis, showing reduced in-hospital mortality [25]. The present study was not designed to compare PCI with conservative management in patients with CKD. Rather, it describes clinical outcomes among CKD patients who underwent PCI. Accordingly, our findings should not be interpreted as suggesting harm from PCI, but instead indicate that CKD remains associated with residual adverse risk despite revascularization. Although long-term mortality was high among patients with stage IV/V CKD, current evidence does not support withholding PCI in the setting of acute myocardial infarction on the basis of renal dysfunction alone. In elective settings, our results underscore the importance of careful patient selection and multidisciplinary decision-making.
Based on the study results and previous publications, we support a risk-adjusted approach in managing patients with CKD undergoing PCI, taking into consideration elective vs. emergent intervention, access site and the severity of renal impairment. In elective cases, strategies may include intensified surveillance with functional testing or symptom-triggered imaging, optimization of medical therapy, consideration of access site, and possibly earlier involvement of nephrology and multidisciplinary heart-kidney teams. Procedural decisions should balance benefits against long-term survival projections, informed by evidence from the ISCHEMIA-CKD trial, while acknowledging its limitations, and the observed TVR rates from this analysis and earlier studies. In acute presentations, clinicians should refrain from postponing PCI out of concern for potential renal injury, a practice sometimes referred to as “renalism” [26].
Several limitations merit consideration. First, this was a retrospective, observational, single-center study. Although the cohort was large and analyses incorporated multivariable adjustment and competing risk methodology, residual confounding cannot be fully excluded. Second, CKD classification was based on estimated glomerular filtration rate measured prior to PCI and did not include albuminuria or proteinuria, which may have resulted in misclassification or underestimation of renal disease severity. Third, data on medication adherence, contrast volume, nephroprotective strategies and contrast-associated kidney injury or CKD progression were unavailable, and these factors may have influenced clinical outcomes. In addition, the study did not include a comparator group of patients with CKD managed without PCI, precluding assessment of the relative benefits or risks of revascularization versus conservative treatment in this population. Finally, although follow-up was comprehensive, cause-specific mortality data were not available, limiting our ability to distinguish cardiovascular from non-cardiovascular causes of death.
5. Conclusions
CKD, particularly in advanced stages, is independently associated with increased mortality and MI after PCI, with effects persisting long-term. While advanced CKD showed higher unadjusted TVR risk, this was not independent after adjustment. These findings support individualized treatment strategies and extended follow-up in PCI patients with CKD.
Supplementary Materials
The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/jcdd13010004/s1, Table S1: Fine and grey competing risk models.
Author Contributions
Conceptualization, K.S. and A.S. (Alon Shechter); Methodology, Y.T.-B., A.S. (Alon Shechter) and A.L.; Software, A.L.; Validation, Y.T.-B., T.T.L. and A.L.; Formal analysis, A.L.; Investigation, K.S., E.I., T.T.L., A.R., Y.S., A.S. (Arthur Shiyovich) and A.L.; Resources, T.T.L. and R.K.; Data curation, A.L.; Writing—original draft, K.S.; Writing—review & editing, Y.T.-B., E.I., T.T.L., A.R., L.P., A.S. (Alon Shechter), Y.S., A.S. (Arthur Shiyovich) and A.L.; Visualization, E.I., T.T.L., A.R., L.P., Y.S., A.S. (Arthur Shiyovich) and R.K.; Supervision, A.S. (Arthur Shiyovich) and R.K. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Rabin medical center (Project identification code 3741) on 20 October 2022.
Informed Consent Statement
The requirement for patient consent was waived by the Ethics Committee in light of the study’s retrospective cohort design.
Data Availability Statement
The data presented in this study are available on request from the corresponding author.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Gansevoort, R.T.; Correa-Rotter, R.; Hemmelgarn, B.R.; Jafar, T.H.; Heerspink, H.J.L.; Mann, J.F.; Matsushita, K.; Wen, C.P. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 2013, 382, 339–352. [Google Scholar] [CrossRef]
- Saeed, D.; Reza, T.; Shahzad, M.W.; Karim Mandokhail, A.; Bakht, D.; Qizilbash, F.H.; Silloca-Cabana, E.O.; Ramadhan, A.; Bokhari, S.F.H. Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health. Cureus 2023, 15, e51362. [Google Scholar] [CrossRef]
- Fox, C.S.; Matsushita, K.; Woodward, M.; Bilo, H.J.; Chalmers, J.; Heerspink, H.J.L.; Lee, B.J.; Perkins, R.M.; Rossing, P.; Sairenchi, T.; et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis. Lancet 2012, 380, 1662–1673. [Google Scholar] [CrossRef]
- Na, K.Y.; Kim, C.W.; Song, Y.R.; Chin, H.J.; Chae, D.-W. The Association between Kidney Function, Coronary Artery Disease, and Clinical Outcome in Patients Undergoing Coronary Angiography. J. Korean Med. Sci. 2009, 24, S87. [Google Scholar] [CrossRef]
- Lee, J.M.; Kang, J.; Lee, E.; Hwang, D.; Rhee, T.-M.; Park, J.; Kim, H.-L.; Lee, S.E.; Han, J.-K.; Yang, H.-M.; et al. Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era. JACC Cardiovasc. Interv. 2016, 9, 2097–2109. [Google Scholar] [CrossRef]
- Kwon, W.; Choi, K.H.; Song, Y.B.; Park, Y.H.; Lee, J.M.; Lee, J.-Y.; Lee, S.-J.; Lee, S.Y.; Kim, S.M.; Yun, K.H.; et al. Intravascular Imaging in Patients With Complex Coronary Lesions and Chronic Kidney Disease. JAMA Netw. Open 2023, 6, e2345554. [Google Scholar] [CrossRef] [PubMed]
- Levey, A.S.; Eckardt, K.-U.; Tsukamoto, Y.; Levin, A.; Coresh, J.; Rossert, J.; Zeeuw, D.D.E.; Hostetter, T.H.; Lameire, N.; Eknoyan, G. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005, 67, 2089–2100. [Google Scholar] [CrossRef] [PubMed]
- Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.L.; Castro, A.F.; Feldman, H.I.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Greene, T.; et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009, 150, 604–612. [Google Scholar] [CrossRef]
- Mitchell, C.; Rahko, P.S.; Blauwet, L.A.; Canaday, B.; Finstuen, J.A.; Foster, M.C.; Horton, K.; Ogunyankin, K.O.; Palma, R.A.; Velazquez, E.J. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 2019, 32, 1–64. [Google Scholar] [CrossRef] [PubMed]
- Vichova, T.; Knot, J.; Ulman, J.; Maly, M.; Motovska, Z. The impact of stage of chronic kidney disease on the outcomes of diabetics with acute myocardial infarction treated with percutaneous coronary intervention. Int. Urol. Nephrol. 2016, 48, 1137–1143. [Google Scholar] [CrossRef]
- Grandjean-Thomsen, N.L.; Marley, P.; Shadbolt, B.; Farshid, A. Impact of Mild-to-Moderate Chronic Kidney Disease on One Year Outcomes after Percutaneous Coronary Intervention. Nephron 2017, 137, 23–28. [Google Scholar] [CrossRef]
- Hashimoto, Y.; Ozaki, Y.; Kan, S.; Nakao, K.; Kimura, K.; Ako, J.; Noguchi, T.; Suwa, S.; Fujimoto, K.; Dai, K.; et al. Impact of Chronic Kidney Disease on In-Hospital and 3-Year Clinical Outcomes in Patients With Acute Myocardial Infarction Treated by Contemporary Percutaneous Coronary Intervention and Optimal Medical Therapy―Insights From the J-MINUET Study―. Circ. J. 2021, 85, 1710–1718. [Google Scholar] [CrossRef]
- Soh, R.Y.-H.; Sia, C.-H.; Lau, R.-H.; Ho, P.-Y.; Timothy, N.Y.-M.; Ho, J.S.-Y.; Kaur, H.; Sim, H.-W.; Yeo, T.-C.; Tan, H.-C.; et al. The impact of chronic kidney disease on long-term outcomes following semi-urgent and elective percutaneous coronary intervention. Coron. Artery Dis. 2021, 32, 517–525. [Google Scholar] [CrossRef]
- Jiang, W.; Zhou, Y.; Chen, S.; Liu, S. Impact of Chronic Kidney Disease on Outcomes of Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis. Tex. Heart Inst. J. 2023, 50, e227873. [Google Scholar] [CrossRef] [PubMed]
- Ronco, C.; Bellasi, A.; Di Lullo, L. Cardiorenal Syndrome: An Overview. Adv. Chronic Kidney Dis. 2018, 25, 382–390. [Google Scholar] [CrossRef]
- Kumar, U.; Wettersten, N.; Garimella, P.S. Cardiorenal Syndrome: Pathophysiology. Cardiol. Clin. 2019, 37, 251–265. [Google Scholar] [CrossRef] [PubMed]
- Rangaswami, J.; Bhalla, V.; Blair, J.E.A.; Chang, T.I.; Costa, S.; Lentine, K.L.; Lerma, E.V.; Mezue, K.; Molitch, M.; Mullens, W.; et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation 2019, 139, e840–e878. [Google Scholar] [CrossRef]
- Vasu, S.; Gruberg, L.; Brown, D.L. The impact of advanced chronic kidney disease on in-hospital mortality following percutaneous coronary intervention for acute myocardial infarction. Catheter. Cardiovasc. Interv. Off. J. Soc. Card. Angiogr. Interv. 2007, 70, 701–705. [Google Scholar] [CrossRef]
- Skalsky, K.; Shiyovich, A.; Steinmetz, T.; Kornowski, R. Chronic Renal Failure and Cardiovascular Disease: A Comprehensive Appraisal. J. Clin. Med. 2022, 11, 1335. [Google Scholar] [CrossRef] [PubMed]
- Milojevic, M.; Head, S.J.; Mack, M.J.; Mohr, F.W.; Morice, M.-C.; Dawkins, K.D.; Holmes, D.R.; Serruys, P.W.; Kappetein, A.P. The impact of chronic kidney disease on outcomes following percutaneous coronary intervention versus coronary artery bypass grafting in patients with complex coronary artery disease: Five-year follow-up of the SYNTAX trial. EuroIntervention 2018, 14, 102–111. [Google Scholar] [CrossRef]
- Saltzman, A.J.; Stone, G.W.; Claessen, B.E.; Narula, A.; Leon-Reyes, S.; Weisz, G.; Brodie, B.; Witzenbichler, B.; Guagliumi, G.; Kornowski, R.; et al. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. JACC Cardiovasc. Interv. 2011, 4, 1011–1019. [Google Scholar] [CrossRef] [PubMed]
- Chaitman, B.R.; Cyr, D.D.; Alexander, K.P.; Pracoń, R.; Bainey, K.R.; Mathew, A.; Acharya, A.; Kunichoff, D.F.; Fleg, J.L.; Lopes, R.D.; et al. Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial. Circ. Cardiovasc. Interv. 2022, 15, e012103. [Google Scholar] [CrossRef]
- Bangalore, S.; Maron, D.J.; O’Brien, S.M.; Fleg, J.L.; Kretov, E.I.; Briguori, C.; Kaul, U.; Reynolds, H.R.; Mazurek, T.; Sidhu, M.S.; et al. Management of Coronary Disease in Patients with Advanced Kidney Disease. N. Engl. J. Med. 2020, 382, 1608–1618. [Google Scholar] [CrossRef]
- Szummer, K.; Lundman, P.; Jacobson, S.H.; Schön, S.; Lindbäck, J.; Stenestrand, U.; Wallentin, L.; Jernberg, T. Influence of Renal Function on the Effects of Early Revascularization in Non-ST-Elevation Myocardial Infarction: Data From the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 2009, 120, 851–858. [Google Scholar] [CrossRef] [PubMed]
- Smilowitz, N.R.; Gupta, N.; Guo, Y.; Mauricio, R.; Bangalore, S. Management and outcomes of acute myocardial infarction in patients with chronic kidney disease. Int. J. Cardiol. 2017, 227, 1–7. [Google Scholar] [CrossRef]
- Gaut, J.P. Time to Abandon Renalism: Patients with Kidney Diseases Deserve More. Clin. J. Am. Soc. Nephrol. 2023, 18, 419–420. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Cumulative incidence of the composite outcome—death, MI and TVR by CKD stage.
Figure 2.
Cumulative incidence of death by CKD stage.
Table 1.
Baseline demographics, clinical history, and procedural characteristics of patients, stratified by CKD stage.
Table 1.
Baseline demographics, clinical history, and procedural characteristics of patients, stratified by CKD stage.
| Preserved Kidney Function (n = 8781) | Stage III (n = 2063) | Stage IV/V (n = 645) | p | |
|---|---|---|---|---|
| Demographics | ||||
| age (years) | 63.4 (11.6) | 75 (10.1) | 72.5 (12.9) | 0.000 |
| Female gender (%) | 20.1 | 33.7 | 33 | 0.000 |
| Cardiovascular risk factors | ||||
| DM (%) | 40.8 | 54.9 | 70.7 | 0.000 |
| HTN (%) | 67.2 | 87.6 | 94.4 | 0.000 |
| Smoking History (%) | 38.6 | 22 | 19.2 | 0.000 |
| COPD (%) | 7.6 | 11.8 | 14 | 0.000 |
| PVD (%) | 4.1 | 7.4 | 15.5 | 0.000 |
| Prior Stroke (%) | 5.6 | 10.4 | 14.6 | 0.000 |
| Cardiac diseases | ||||
| Known CHF (%) | 7.7 | 14.9 | 11.6 | 0.000 |
| EF (%) | 54.9 (8.9) | 52.7 (10.3) | 49.9 (11.5) | 0.000 |
| Known Atrial Fibrillation (%) | 4.4 | 7.6 | 8.2 | 0.000 |
| S/P CABG (%) | 9.1 | 15.7 | 18.8 | 0.000 |
| Other diseases | ||||
| Prior Malignancy (%) | 9.7 | 18.2 | 22.2 | 0.000 |
| Active Malignancy (%) | 4 | 5.5 | 2.9 | 0.002 |
| Dementia (%) | 1.5 | 4.7 | 5.1 | 0.000 |
| Blood tests results | ||||
| Total Cholesterol (mg/dL) | 170.8 (44.7) | 156.9 (44.2) | 147.8 (44.3) | 0.000 |
| HDL (mg/dL) | 41.5 (12.4) | 42.8 (13.9) | 39.3 (12.8) | 0.000 |
| LDL (mg/dL) | 99.7 (37.8) | 85.7 (36.5) | 78.2 (35.7) | 0.000 |
| Triglycerides (mg/dL) | 153.7 (106.6) | 143.1 (85.2) | 157.6 (96.2) | 0.001 |
| HbA1C (%) | 6.8 (1.7) | 7.3 (1.8) | 7.2 (1.9) | 0.000 |
| Hgb (g/dL) | 13.7 (1.7) | 12.4 (2) | 10.7 (1.7) | 0.000 |
| MPV (fL) | 8.9 (1.2) | 9.1 (1.3) | 9.2 (1.3) | 0.000 |
| Plt (103/µL) | 232.2 (73.7) | 227.5 (86.1) | 221.8 (84.9) | 0.000 |
| Creatinine (mg/dL) | 0.9 (0.2) | 1.4 (0.3) | 4.3 (2.6) | 0.000 |
| Uric Acid (mg/dL) | 5.8 (1.5) | 7.2 (1.9) | 7.7 (2.7) | 0.000 |
| WBC (103/µL) | 8.7 (4.7) | 9.2 (9.4) | 8.6 (4.1) | 0.002 |
| Coronary intervention | ||||
| Acute MI (%) | 44.8 | 42.7 | 38 | 0.002 |
| STEMI (%) | 21.4 | 16.5 | 12.9 | 0.000 |
| ACS (excluding MI) (%) | 24 | 21.7 | 18.3 | 0.001 |
| CX_treated (%) | 30.6 | 30.8 | 34.1 | 0.183 |
| LAD_treated (%) | 48.3 | 46.2 | 42.8 | 0.009 |
| RCA_treated (%) | 32.4 | 28.1 | 29.1 | 0.000 |
| LM_treated (%) | 5.3 | 10.5 | 12.6 | 0.000 |
| Graft treated (%) | 2.1 | 5.6 | 5.7 | 0.000 |
| Multivessel PCI (%) | 10.3 | 10.2 | 12.2 | 0.308 |
| CTO treated (%) | 13.6 | 11.9 | 10.4 | 0.012 |
| DES (%) | 76.9 | 72.5 | 73 | 0.000 |
| DEB (%) | 2.9 | 3.3 | 3.3 | 0.494 |
| Radial approach (%) | 64.4 | 51.2 | 40.9 | 0.000 |
Abbreviations: DM—Diabetes Mellitus; HTN—Hypertension; COPD—Chronic Obstructive Pulmonary Disease; PVD—Peripheral Vascular Disease; CHF—Congestive Heart Failure; EF—Ejection Fraction; S/P CABG—Status Post Coronary Artery Bypass Grafting; HDL—High-Density Lipoprotein; LDL—Low-Density Lipoprotein; HgA1C—Hemoglobin A1C; Hgb—Hemoglobin; MPV—Mean Platelet Volume; Plt—Platelets; WBC—White Blood Cells; MI—Myocardial Infarction; STEMI—ST-Elevation Myocardial Infarction; ACS—Acute Coronary Syndrome; CX—Circumflex Artery; LAD—Left Anterior Descending Artery; RCA—Right Coronary Artery; LM—Left Main Artery; Graft—Coronary Artery Bypass Graft; PCI—Percutaneous Coronary Intervention; CTO—Chronic Total Occlusion; DES—Drug-Eluting Stent; DEB—Drug-Eluting Balloon.
Table 2.
All-cause mortality, acute MI and TVR at 1 year and at 5 years in each CKD stage.
| Outcomes | Preserved Kidney Function (n = 8781), % | Stage III (n = 2063), % | Stage IV/V (n = 645), % | p |
|---|---|---|---|---|
| Non-fatal MI, TVR and all-cause mortality at 1 year | 10.3 | 20.6 | 40.8 | 0.000 |
| All-cause mortality at 1 year | 4 | 14.1 | 33 | 0.000 |
| MI at 1 year | 5.8 | 7.1 | 10.5 | 0.000 |
| TVR at 1 year | 2.4 | 2.3 | 3.3 | 0.387 |
| Non-fatal MI and all-cause mortality at 1 year | 9.4 | 20.1 | 40.2 | 0.000 |
| All-cause mortality at 5 years | 10.5 | 33.3 | 57.2 | 0.000 |
| MI at 5 years | 11.1 | 12.6 | 15.2 | 0.002 |
| TVR at 5 years | 4.7 | 4.8 | 4.3 | 0.901 |
| Non-fatal MI and all-cause mortality at 5 years | 20.1 | 40.8 | 63.3 | 0.000 |
Abbreviations: MI—Myocardial Infarction; TVR—Target Vessel Revascularization.
Table 3.
Multivariable analysis for the composite outcome—all-cause mortality, MI and TVR at 1 year and at 5 years.
Table 3.
Multivariable analysis for the composite outcome—all-cause mortality, MI and TVR at 1 year and at 5 years.
| Variable | 1-Year HR (95% CI) | p-Value | 5-Year HR (95% CI) | p-Value |
|---|---|---|---|---|
| CKD Stage | ||||
| IV/V | 3.00 (2.58–3.49) | <0.001 | 2.78 (2.48–3.13) | <0.001 |
| III | 1.46 (1.29–1.65) | <0.001 | 1.49 (1.37–1.63) | <0.001 |
| Adjusted Variables | ||||
| Age (per year) | 1.018 (1.014–1.022) | <0.001 | 1.020 (1.017–1.022) | <0.001 |
| Female gender | 1.15 (1.03–1.28) | 0.015 | 1.07 (0.99–1.16) | 0.107 |
| Diabetes mellitus | 1.14 (1.03–1.27) | 0.010 | 1.27 (1.18–1.37) | <0.001 |
| MI or ACS (non-elective PCI) | 1.43 (1.29–1.60) | <0.001 | 1.17 (1.09–1.26) | <0.001 |
| Moderate-to-severe LV dysfunction | 1.76 (1.57–1.96) | <0.001 | 1.64 (1.52–1.78) | <0.001 |
| Atrial fibrillation | 0.92 (0.76–1.13) | 0.432 | 1.08 (0.95–1.23) | 0.218 |
| Peripheral vascular disease | 1.33 (1.09–1.63) | 0.005 | 1.56 (1.35–1.79) | <0.001 |
| COPD | 1.28 (1.10–1.48) | 0.001 | 1.36 (1.23–1.51) | <0.001 |
| Radial approach | 0.64 (0.58–0.70) | <0.001 | 0.76 (0.71–0.82) | <0.001 |
| Prior stroke | 1.23 (1.05–1.44) | 0.012 | 1.25 (1.12–1.40) | <0.001 |
| Congestive heart failure | 1.13 (0.98–1.31) | 0.101 | 1.32 (1.20–1.46) | <0.001 |
Abbreviations: ACS—Acute coronary syndrome; CKD—Chronic kidney disease; CI—Confidence interval; COPD—Chronic obstructive pulmonary disease; HR—Hazard ratio; LV—Left ventricular; MI—Myocardial infarction; PCI—Percutaneous coronary intervention; TVR—Target vessel revascularization All-cause mortality remained significantly elevated across CKD stages. In CKD stage IV/V, mortality risk was 4.73-fold higher at 1 year (95% CI 3.90–5.73, p < 0.001) and 4.13-fold higher at 5 years (95% CI 3.60–4.73, p < 0.001). For CKD stage III, the corresponding HRs were 2.18 (95% CI 1.85–2.58, p < 0.001) at 1 year and 2.15 (95% CI 1.93–2.38, p < 0.001) at 5 years (Table 4).
Table 5.
Multivariable analysis for MI at 1 year and at 5 years.
| Variable | MI at 1 Year HR (95% CI) | p-Value | MI at 5 Years HR (95% CI) | p-Value |
|---|---|---|---|---|
| CKD Stage | ||||
| IV/V | 1.83 (1.40–2.39) | <0.001 | 1.68 (1.35–2.09) | <0.001 |
| III | 1.06 (0.87–1.29) | 0.578 | 1.08 (0.93–1.26) | 0.292 |
| Adjusted Variables | ||||
| Age (per year) | 1.01 (1.00–1.01) | 0.147 | 1.00 (0.99–1.00) | 0.894 |
| Female gender | 1.02 (0.86–1.21) | 0.828 | 0.95 (0.83–1.08) | 0.407 |
| Diabetes mellitus | 1.31 (1.13–1.53) | <0.001 | 1.42 (1.27–1.59) | <0.001 |
| MI or ACS (non-elective PCI) | 2.02 (1.69–2.42) | <0.001 | 1.65 (1.46–1.87) | <0.001 |
| Moderate-to-severe LV dysfunction | 1.09 (0.91–1.32) | 0.350 | 1.13 (0.99–1.30) | 0.076 |
| Atrial fibrillation | 1.42 (1.11–1.83) | 0.006 | 1.48 (1.23–1.77) | <0.001 |
| Peripheral vascular disease | 1.07 (0.75–1.52) | 0.722 | 1.26 (0.98–1.63) | 0.072 |
| COPD | 0.95 (0.73–1.23) | 0.687 | 1.00 (0.83–1.21) | 0.979 |
| Radial approach | 0.77 (0.66–0.89) | <0.001 | 0.81 (0.73–0.90) | <0.001 |
| Prior stroke | 1.35 (1.07–1.72) | 0.013 | 1.25 (1.04–1.50) | 0.019 |
| Congestive heart failure | 2.00 (1.65–2.42) | <0.001 | 2.04 (1.77–2.35) | <0.001 |
Abbreviations: ACS—Acute coronary syndrome; CKD—Chronic kidney disease; CI—Confidence interval; COPD—Chronic obstructive pulmonary disease; HR—Hazard ratio; LV—Left ventricular; MI—Myocardial infarction; PCI—Percutaneous coronary intervention.
Table 6.
Multivariable analysis for TVR at 1 year and at 5 years.
| Variable | 1-Year HR (95% CI) | p-Value | 5-Year HR (95% CI) | p-Value |
|---|---|---|---|---|
| CKD Stage | ||||
| IV/V | 1.16 (0.73–1.85) | 0.530 | 1.08 (0.73–1.60) | 0.714 |
| III | 0.74 (0.53–1.04) | 0.084 | 0.97 (0.76–1.23) | 0.774 |
| Adjusted Variables | ||||
| Age (per year) | 1.01 (1.00–1.02) | 0.077 | 1.00 (0.99–1.01) | 0.894 |
| Female gender | 0.85 (0.64–1.13) | 0.267 | 0.82 (0.66–1.02) | 0.069 |
| Diabetes mellitus | 1.88 (1.47–2.41) | <0.001 | 1.77 (1.48–2.11) | <0.001 |
| MI or ACS (non-elective PCI) | 1.49 (1.15–1.95) | 0.003 | 1.18 (0.98–1.42) | 0.073 |
| Moderate-to-severe LV dysfunction | 1.22 (0.92–1.63) | 0.169 | 1.06 (0.85–1.33) | 0.589 |
| Atrial fibrillation | 1.14 (0.75–1.75) | 0.534 | 1.40 (1.05–1.88) | 0.022 |
| Peripheral vascular disease | 0.79 (0.42–1.49) | 0.464 | 1.12 (0.74–1.69) | 0.598 |
| COPD | 0.95 (0.64–1.43) | 0.823 | 0.96 (0.71–1.30) | 0.787 |
| Radial approach | 0.81 (0.63–1.02) | 0.077 | 0.93 (0.78–1.10) | 0.382 |
| Prior stroke | 1.58 (1.10–2.26) | 0.012 | 1.44 (1.09–1.90) | 0.010 |
| Congestive heart failure | 2.16 (1.60–2.91) | <0.001 | 1.96 (1.56–2.45) | <0.001 |
Abbreviations: ACS—Acute coronary syndrome; CKD—Chronic kidney disease; CI—Confidence interval; COPD—Chronic obstructive pulmonary disease; HR—Hazard ratio; LV—Left ventricular; MI—Myocardial infarction; PCI—Percutaneous coronary intervention; PVD—Peripheral vascular disease; TVR—Target vessel revascularization.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
MDPI and ACS Style
Skalsky, K.; Talmor-Barkan, Y.; Itelman, E.; Lerman, T.T.; Rotmensh, A.; Perl, L.; Shechter, A.; Shapira, Y.; Shiyovich, A.; Kornowski, R.; et al. Prognostic Implications of Chronic Kidney Disease Stage on Outcomes After Percutaneous Coronary Intervention. J. Cardiovasc. Dev. Dis. 2026, 13, 4. https://doi.org/10.3390/jcdd13010004
AMA Style
Skalsky K, Talmor-Barkan Y, Itelman E, Lerman TT, Rotmensh A, Perl L, Shechter A, Shapira Y, Shiyovich A, Kornowski R, et al. Prognostic Implications of Chronic Kidney Disease Stage on Outcomes After Percutaneous Coronary Intervention. Journal of Cardiovascular Development and Disease. 2026; 13(1):4. https://doi.org/10.3390/jcdd13010004
Chicago/Turabian StyleSkalsky, Keren, Yeela Talmor-Barkan, Edward Itelman, Tsahi T. Lerman, Assaf Rotmensh, Leor Perl, Alon Shechter, Yaron Shapira, Arthur Shiyovich, Ran Kornowski, and et al. 2026. "Prognostic Implications of Chronic Kidney Disease Stage on Outcomes After Percutaneous Coronary Intervention" Journal of Cardiovascular Development and Disease 13, no. 1: 4. https://doi.org/10.3390/jcdd13010004
APA StyleSkalsky, K., Talmor-Barkan, Y., Itelman, E., Lerman, T. T., Rotmensh, A., Perl, L., Shechter, A., Shapira, Y., Shiyovich, A., Kornowski, R., & Levi, A. (2026). Prognostic Implications of Chronic Kidney Disease Stage on Outcomes After Percutaneous Coronary Intervention. Journal of Cardiovascular Development and Disease, 13(1), 4. https://doi.org/10.3390/jcdd13010004
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
